Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema

Immunopharmacology

Volumn 43, Issue 2-3, 1999, Pages 293-302

  Blais Jr , Charles ^a   Rouleau, Jean Lucien ^b   Brown, Nancy J ^c   Lepage, Yves ^a   Spence, David ^d   Munoz, Claudio ^d   Friborg, Jacques ^e   Geadah, David ^e   Gervais, Nicole ^a   Adam, Albert ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MONTREAL HEART INSTITUTE   (Canada)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d ROBARTS RESEARCH INSTITUTE   (Canada)

^e MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

Angioedema; Angiotensin converting enzyme inhibitor; Bradykinin; Des Arg9 bradykinin; Serum metabolism

Indexed keywords

BRADYKININ; BRADYKININ[1-8]; CAPTOPRIL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; LISINOPRIL; QUINAPRIL; RAMIPRIL; RAMIPRILAT;

ANGIONEUROTIC EDEMA; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DEGRADATION; DRUG HALF LIFE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HYDROLYSIS; HYPERSENSITIVITY REACTION; MALE; PRIORITY JOURNAL;

ADULT; AGED; ANGIONEUROTIC EDEMA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BRADYKININ; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HUMANS; LYSINE CARBOXYPEPTIDASE; MALE; MIDDLE AGED;

EID: 0345008869     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-3109(99)00133-2     Document Type: Conference Paper

References (31)

1. Anderson, M.W., deShazo, R.D., 1990. Studies of the mechanism of angiotensin-converting enzyme (ACE) inhibitor-associated angioedema: the effect of an ACEi on cutaneous responses to bradykinin, codeine, and histamine. J. Allergy Clin. Immunol. 85, 856-858.
2. Bahal O'Mara, N., O'Mara, E.M. Jr., 1996. Delayed onset of angioedema with angiotensin-converting enzyme inhibitors: case report and review of the literature. Pharmacotherapy 16, 675-679.
3. Blais, C. Jr., Couture, R., Drapeau, G., Colman, R.W., Adam, A., 1997a. Involvement of endogenous kinins in the pathogenesis of peptidoglycan-induced arthritis in the Lewis rat. Arthritis Rheum. 40, 1327-1333.
4. Blais, C. Jr., Drapeau, G., Raymond, P., Lamontagne, D., Gervais, N., Venneman, I., Adam, A., 1997b. Contribution of angiotensin-converting enzyme to the cardiac metabolism of bradykinin: an interspecies study. Am. J. Physiol. 273, H2263-H2271, Heart Circ. Physiol. 42.
5. Blais, C. Jr., Drapeau, G., Raymond, P., Lamontagne, D., Gervais, N., Venneman, I., Adam, A., 1997b. Contribution of angiotensin-converting enzyme to the cardiac metabolism of bradykinin: an interspecies study. Am. J. Physiol. 273, H2263-H2271, Heart Circ. Physiol. 42.
6. 9-bradykinin metabolism in patients who presented hypersensitivity reactions during hemodialysis: role of serum ACE and aminopeptidase P. Peptides, in press.
7. Brown, N.J., Blais, C. Jr., Gandhi, S.K., Adam, A., 1998. ACE insertion/deletion genotype affects bradykinin metabolism. J. Cardiovasc. Pharmacol. 32, 373-377.
8. Chin, H.L., Buchan, D.A., 1990. Severe angioedema after long-term use of an angiotensin-converting enzyme inhibitor. Ann. Intern. Med. 112, 312-313.
9. Décarie, A., Drapeau, G., Closset, J., Couture, R., Adam, A., 1994. Development of digoxigenin-labeled peptide: application to chemiluminoenzyme immunoassay of bradykinin in inflamed tissues. Peptides 15, 511-518.
10. 9]BK: influence of enalaprilat. Am. J. Physiol. 270, H1340-H1347, Heart Circ. Physiol. 39.
11. 9]BK: influence of enalaprilat. Am. J. Physiol. 270, H1340-H1347, Heart Circ. Physiol. 39.
12. Erdös, E.G., Skidgel, R.A., 1997. Metabolism of bradykinin by peptidases in health and disease. In: Farmer, S.G. (Ed.), Handbook of Immunopharmacology: The Kinin System. Academic Press, London, pp. 111-141.
13. Ferner, R.E., Simpson, J.M., Rawlins, M.D., 1987. Effects of intradermal bradykinin after inhibition of angiotensin converting enzyme. Br. Med. J. 294, 1119-1120.
14. Greaves, M., Lawlor, F., 1991. Angioedema: manifestations and management. J. Am. Acad. Dermatol. 25, 155-165.
15. Hedner, T., Samuelsson, O., Lunde, H., Lindholm, L., Andrén, L., Wiholm, B.-E., 1992. Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors. Br. Med. J. 304, 941-946.
16. Israili, Z.H., Hall, W.D., 1992. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. Ann. Intern. Med. 117, 234-242.
17. Lalloo, U.G., Barnes, P.J., Chung, K.F., 1996. Pathophysiology and clinical presentations of cough. J. Allergy Clin. Immunol. 98, S91-S97.
18. Linz, W., Weimer, G., Gohlke, P., Unger, T., Schölkens, B.A., 1995. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol. Rev. 47, 25-49.
19. 1 receptors: a review. Immunopharmacology 30, 1-26.
20. Moore, J.W., Pearson, R.G., 1981. Complex reactions. In: Moore, J.W., Pearson, R.G. (Eds.), Kinetics and Mechanism. Wiley, New York, pp. 284-296.
21. Nussberger, J., Cugno, M., Amstutz, C., Cicardi, M., Pellacani, A., Agostoni, A., 1998. Plasma bradykinin in angio-oedema. Lancet 351, 1693-1697.
22. Orfan, N., Patterson, R., Dykewicz, M.S., 1990. Severe angioedema related to ACE inhibitors in patients with a history of idiopathic angioedema. JAMA 264, 1287-1289.
23. 9-BK using a chemiluminescence enzyme immunoassay: application to its kinetic profile during plasma activation. J. Immunol. Methods 180, 247-257.
24. Ryan, J.W., Berryer, P., Chung, A.Y.K., Sheffy, D.H., 1994. Characterization of rat pulmonary vascular aminopeptidase P in vivo: role in the inactivation of bradykinin. J. Pharmacol. Exp. Ther. 269, 941-947.
25. Sabroe, R.A., Kobza Black, A., 1997. Angiotensin-converting enzyme (ACE) inhibitors and angio-oedema. Br. J. Dermatol. 136, 153-158.
26. Schapira, M., Silver, L.D., Scott, C.F., Schmaier, A.H., Prograis, L.J. Jr., Curd, J.G. et al., 1983. Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. N. Engl. J. Med. 308, 1050-1053.
27. Schiller, P.I., Langauer Messmer, S., Haefeli, W.E., Schlienger, R.G., Bircher, A.J., 1997. Angiotensin-converting enzyme inhibitor-induced angioedema: late onset, irregular course, and potential role of triggers. Allergy 52, 432-435.
28. Slater, E.E., Merrill, D.D., Guess, H.A., Roylance, P.J., Cooper, W.D., Inman, W.H.W. et al., 1988. Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. JAMA 260, 967-970.
29. White, G.C., Marder, V.J., Colman, R.W., Hirsh, J., Salzman, E.W., 1994. Approach to the bleeding patient. In: Colman, R.W., Hirsh, J., Marder, V.J., Salzman, E.W. (Eds.), Hemostasis and Thrombosis: Basic Principles and Clinical Practice. JB Lippincott, Philadelphia, pp. 1134-1147.
30. Wilkin, J.K., Hammond, J.J., Kirkendall, W.M., 1980. The captopril-induced eruption. Arch. Dermatol. 116, 902-905.
31. Wood, S.M., Mann, R.D., Rawlins, M.D., 1987. Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors. Br. Med. J. 294, 91-92.